Latest Crohn’s and Colitis News and Research
Metastatic cutaneous Crohn’s disease of the face – a successful case treated with ustekinumab. J Crohns Colitis. 2019 Oct 20;: Authors: Martins Figueiredo L, Oliveira AM, Martins A PMID: 31630151 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31630151?dopt=Abstract
Read MoreThe TLR9 agonist cobitolimod induces IL10 producing wound healing macrophages and regulatory T cells in ulcerative colitis. J Crohns Colitis. 2019 Oct 20;: Authors: Schmitt H, Ulmschneider J, Billmeier U, Vieth M, Scarozza P, Sonnewald S, Reid S, Atreya I, Rath T, Zundler S, Langheinrich M, Schüttler J, Hartmann A, Winkler T, Admyre C, Knittel T, Dieterich Johansson C, Zargari A, Neurath MF, Atreya R Abstract BACKGROUND AND AIMS: The topically applied Toll-like receptor 9 (TLR9) agonist cobitolimod is a first-in-class DNA-based oligonucleotide that demonstrated therapeutic efficacy in clinical trials…
Read MoreEvaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn’s disease using real world data. J Crohns Colitis. 2019 Oct 20;: Authors: Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH, Swiss IBD Cohort study group Abstract BACKGROUND AND AIMS: We evaluated the cost-effectiveness of early (≤2 years after diagnosis) compared to late or no biologic initiation (starting biologics >2 years after diagnosis or no biologic use) for adults with Crohn’s disease in Switzerland. METHODS: We developed a Markov cohort…
Read MoreRelated Articles Microscopic inflammation at ileocaecal resection margins in Crohn’s disease: prevent recurrence or treat residual disease? J Crohns Colitis. 2019 Oct 19;: Authors: Kotze PG, Yamamoto T PMID: 31628470 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31628470?dopt=Abstract
Read MoreThe Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. J Crohns Colitis. 2019 Oct 19;: Authors: de Bruyn M, Ringold R, Martens E, Ferrante M, Van Assche G, Opdenakker G, Dukler A, Vermeire S Abstract BACKGROUND: Surrogate markers that accurately detect mucosal healing [MH] in patients with ulcerative colitis [UC] are urgently needed. Several stool neutrophil-related proteins are currently used as biomarkers for MH. However, the sensitivity and specificity are not sufficient to avoid unnecessary endoscopic evaluations. METHODS: Novel serum neutrophil-related markers…
Read MoreMicroRNA23a Overexpression in Crohn’s Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier. J Crohns Colitis. 2019 Oct 18;: Authors: Felwick RK, Dingley GJR, Martinez-Nunez R, Sanchez-Elsner T, Cummings JRF, Collins JE Abstract BACKGROUND AND AIMS: Mucosal healing is important in Crohn’s disease therapies. Epithelial homeostasis becomes dysregulated in Crohn’s, with increased permeability, inflammation, and diarrhoea. MicroRNAs are small non-coding RNAs that regulate gene expression and show changes in inflammatory bowel disease. Tumour necrosis factor alpha [TNFα] inhibitor protein 3 is…
Read MoreBariatric Surgery and Its Complications in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 Oct 18;: Authors: Singh A, Koenen B, Kirby DF Abstract Recent data have suggested that bariatric procedures, especially laparoscopic sleeve gastrectomy (SG), are safe and effective weight loss measures in patients with inflammatory bowel disease (IBD). But most of the studies have looked at short-term outcomes, and there is a general lack of awareness of underlying disease processes and baseline comorbidities in IBD patients undergoing bariatric procedures. Postbariatric issues in IBD patients including diarrhea from dumping…
Read MoreIs Ulcerative Colitis Associated With Primary Sclerosing Cholangitis an Undertreated Condition? Inflamm Bowel Dis. 2019 Oct 18;: Authors: Van Der Have M, Oldenburg B PMID: 31626699 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31626699?dopt=Abstract
Read MoreUnique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience. Inflamm Bowel Dis. 2019 Oct 18;: Authors: Wang MH, Mousa OY, Friton JJ, Raffals LE, Leighton JA, Pasha SF, Picco MF, Cushing KC, Monroe K, Nix BD, Newberry RD, Faubion WA Abstract INTRODUCTION: Ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) is a rare phenotype. We aimed to assess patients with UC-PSC or UC alone and describe differences in clinical and phenotypic characteristics, antitumor necrosis factor (TNF) therapy, and long-term…
Read MoreErratum: The Influence of Antidepressants on the Disease Course Among Patients With Crohn’s Disease and Ulcerative Colitis-A Danish Nationwide Register-Based Cohort Study. Inflamm Bowel Dis. 2019 Oct 18;25(11):e152 Authors: Kristensen MS, Kjærulff TM, Ersbøll AK, Green A, Hallas J, Thygesen LC PMID: 31626706 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31626706?dopt=Abstract
Read More